Evidence map›Paper›PMID 32438106›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2020

Surface tethering of stromal cell-derived factor-1α carriers to stem cells enhances cell homing to ischemic muscle.

Jye Yng Teo, Eunkyung Ko, Jiayu Leong, Jiman Hong, Jessie S Jeon, Yi Yan Yang, Hyunjoon Kong

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Jye Yng TeoDepartment of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA; Institute of Bioengineering and Nanotechnology, Singapore, Singapore.
Eunkyung KoDepartment of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Jiayu LeongDepartment of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA; Institute of Bioengineering and Nanotechnology, Singapore, Singapore.
Jiman HongDepartment of Mechanical Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.
Jessie S JeonKAIST Institute for Health Science and Technology, Daejeon, South Korea.
Yi Yan YangInstitute of Bioengineering and Nanotechnology, Singapore, Singapore.
Hyunjoon KongDepartment of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA; Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA; Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL, USA; Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA. Electronic address: hjkong06@illinois.edu.
University of Illinois Urbana-Champaign · USInstitute of Bioengineering and Nanotechnology · SGKorea Advanced Institute of Science and Technology · KR

Funding

Tissue microenvironment (TIMe) training programT32EB019944 · NIBIB · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI BHARGAVA, ROHIT, GASKINS, REX · 2016 to 2025
$1.9M
Nanocells for vascular normalization therapiesR01HL109192 · NHLBI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI KONG, HYUNJOON · 2011 to 2015
$1.9M
Development of a Liposomal Nanostimulator to Improve Stem Cell-Based Revascularization TherapiesR21HL131469 · NHLBI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI KONG, HYUNJOON · 2016 to 2017
$428k
NHLBI NIH HHS R01 HL109192NHLBI NIH HHS R21 HL131469NIBIB NIH HHS T32 EB019944
6 · The paper itself

Abstract

Mesenchymal stem cells are promising medicine for treating diseases and tissue defects because of their innate ability to secrete therapeutic factors. Intravenous delivery of stem cells, although favored for its minimal invasiveness, is often plagued by low cellular engraftment in the target tissue. To this end, this study hypothesizes that in situ activation of cellular expression of CXC chemokine 4 (CXCR4) would significantly improve cellular migration to injured tissue. This hypothesis was examined by tethering the surface of stem cells with poly(D,L-lactide-co-glycolide)-block-hyaluronic acid (HA) particles containing stromal cell-derived factor-1α, a model chemokine to sensitize CXCR4. The HA blocks in the particles enhanced the association rate constant to stem cells by 3.3-fold, and in turn, increased the number of cells expressing CXCR4 receptors. Consequently, these cells displayed 1.2-fold higher transendothelial migration in vitro and 1.7-fold greater trafficking to the ischemic hindlimb of a mouse than that of the untethered cells.

Indexed as

AnimalsChemokine CXCL12HindlimbIschemiaKineticsMagnetic Resonance SpectroscopyMesenchymal Stem CellsMiceReceptors, CXCR4Stem CellsChemokine CXCL12Receptors, CXCR4CXC chemokine 4IschemiaMesenchymal stem cellsParticlesStromal cell-derived factor-1α

Identifiers

PMID32438106
PMCPMC7438260
OpenAlexW3021172648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.